KR20210126654A - 암 치료 - Google Patents

암 치료 Download PDF

Info

Publication number
KR20210126654A
KR20210126654A KR1020217028671A KR20217028671A KR20210126654A KR 20210126654 A KR20210126654 A KR 20210126654A KR 1020217028671 A KR1020217028671 A KR 1020217028671A KR 20217028671 A KR20217028671 A KR 20217028671A KR 20210126654 A KR20210126654 A KR 20210126654A
Authority
KR
South Korea
Prior art keywords
erdafitinib
cancer
daily
treatment
serum phosphate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217028671A
Other languages
English (en)
Korean (ko)
Inventor
앤 엘리자베스 오'하간
피터 마리 지. 드 포르
안자리 나라얀 아바다니
Original Assignee
얀센 파마슈티카 엔.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 얀센 파마슈티카 엔.브이. filed Critical 얀센 파마슈티카 엔.브이.
Publication of KR20210126654A publication Critical patent/KR20210126654A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020217028671A 2019-02-12 2020-02-11 암 치료 Ceased KR20210126654A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19156806 2019-02-12
EP19156806.2 2019-02-12
EP19176575 2019-05-24
EP19176575.9 2019-05-24
PCT/EP2020/053490 WO2020165181A1 (en) 2019-02-12 2020-02-11 Cancer treatment

Publications (1)

Publication Number Publication Date
KR20210126654A true KR20210126654A (ko) 2021-10-20

Family

ID=69467563

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217028671A Ceased KR20210126654A (ko) 2019-02-12 2020-02-11 암 치료

Country Status (16)

Country Link
US (1) US20220168298A1 (https=)
EP (1) EP3923942A1 (https=)
JP (2) JP2022521173A (https=)
KR (1) KR20210126654A (https=)
CN (1) CN113423402A (https=)
AU (1) AU2020223467B2 (https=)
BR (1) BR112021015686A2 (https=)
CA (1) CA3126959A1 (https=)
IL (1) IL285466A (https=)
JO (1) JOP20210216A1 (https=)
MA (1) MA54932A (https=)
MX (1) MX2021009670A (https=)
PH (1) PH12021551949A1 (https=)
SG (1) SG11202107850VA (https=)
TW (1) TWI863962B (https=)
WO (1) WO2020165181A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023553533A (ja) * 2020-12-11 2023-12-21 エラスカ，インク． 癌の処置のための併用療法
CN117083283A (zh) * 2020-12-11 2023-11-17 医睿世康药业研发公司 用于癌症治疗的联合疗法
CN112957368A (zh) * 2021-04-02 2021-06-15 南昌大学 一种司维拉姆的新用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4063516A1 (en) * 2014-09-26 2022-09-28 Janssen Pharmaceutica NV Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor
TWI719960B (zh) * 2015-02-10 2021-03-01 英商阿斯迪克治療公司 新穎組成物
AU2016341445B2 (en) * 2015-10-23 2020-08-27 Array Biopharma, Inc. 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases
AU2018216969B2 (en) * 2017-02-06 2024-04-11 Janssen Pharmaceutica Nv Cancer treatment
JOP20190280A1 (ar) * 2017-06-02 2019-12-02 Janssen Pharmaceutica Nv مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية
MA47408B1 (fr) * 2017-12-20 2023-08-31 Janssen Pharmaceutica Nv Traitement du cancer

Also Published As

Publication number Publication date
JP2022521173A (ja) 2022-04-06
EP3923942A1 (en) 2021-12-22
PH12021551949A1 (en) 2022-07-18
AU2020223467B2 (en) 2025-12-04
CA3126959A1 (en) 2020-08-20
SG11202107850VA (en) 2021-08-30
MX2021009670A (es) 2021-09-08
JOP20210216A1 (ar) 2023-01-30
CN113423402A (zh) 2021-09-21
AU2020223467A1 (en) 2021-08-05
TW202045173A (zh) 2020-12-16
JP2026016402A (ja) 2026-02-03
MA54932A (fr) 2021-12-22
TWI863962B (zh) 2024-12-01
IL285466A (en) 2021-09-30
WO2020165181A1 (en) 2020-08-20
BR112021015686A2 (pt) 2021-10-26
US20220168298A1 (en) 2022-06-02

Similar Documents

Publication Publication Date Title
JP7668777B2 (ja) 癌治療
TWI798199B (zh) 癌症治療
JP2026016402A (ja) 癌治療
WO2016025621A1 (en) Methods of treatment using an erk inhibitor
EA052711B1 (ru) Лечение рака
HK40103983A (en) Cancer treatment
EA051616B1 (ru) Лечение рака
HK40018978B (en) Cancer treatment
HK40018978A (en) Cancer treatment
EP4504202A1 (en) Combination therapies comprising gdc-6036 and gdc-0077 for the treatment of cancer
EP4504189A1 (en) Methods of treating solid tumor using (19r)-5-chloro-3-ethyl-16-fluoro-10,19-dimethyl-20-oxa-3,4,10,11,23-pentaazapentacyclo[19.3.1.02,6.08,12.013,18]pentacosa-1(24),2(6),4,8,11,13,15,17,21(25),22-decaen-22-amine
HK40013982A (en) Cancer treatment

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601